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Abstract
Background: Malaria is a major public health problem in Mali and diagnosis is typically based on microscopy.
Microscopy requires a well trained technician, a reliable power source, a functioning microscope and adequate
supplies. The scarcity of resources of community health centres (CHC) does not allow for such a significant
investment in only one aspect of malaria control. In this context, Rapid Diagnostic Tests (RDTs) may improve case
management particularly in remote areas.
Methods: This multicentre study included 725 patients simultaneously screened with OptiMal-IT test and thick
smears for malaria parasite detection. While evaluating the therapeutic efficacy of choroquine in 2 study sites, we
compared the diagnostic values of thick smear microscopy to OptiMal-IT test applying the WHO 14 days follow-up
scheme using samples collected from 344 patients.
Results: The sensitivity and the specificity of OptiMal-IT compared to thick smear was 97.2% and 95.4%, whereas
the positive and negative predictive values were 96.7 and 96.1%, respectively. The percent agreement between the
two diagnostic tests was 0.93. The two tests were comparable in detecting malaria at day 0, day 3 and day 14. The
only difference was observed at day 7 due to high gametocytemia. Subjectively, health care providers found
OptiMal-IT easier to use and store under field conditions.
Conclusion: OptiMal-IT test revealed similar results when compared to microscopy which is considered the gold
standard for malaria diagnostics. The test was found to have a short processing time and was easier to use. These
advantages may improve malaria case management by providing a diagnostic and drug efficacy follow-up tool to
peripheral health centres with limited resources.
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Background
In sub-Saharan Africa, malaria is responsible of 25% of
all cause mortality in children less than 5 years old [1].
Studies conducted by the Department of Epidemiology
of Parasitic Diseases at the University of Bamako, Mali
in collaboration with the National Malaria Control Pro-
gramme (NMCP) of Mali, have demonstrated that the
prevalence of malaria in rural areas was more than 70%
in children under five years of age and the incidence of
clinical infection ranges from 1.5 to 2 episodes per child
per year [2]. In addition, severe malaria was reported to
account for 15% of hospitalizations in children between
the ages of 0 and 14 years in the capital city of Bamako
leading to a case fatality rate of approximately 17% at
the National Paediatric Hospital in Bamako, and 25%
countrywide [3,4].
Mali health policy makers have prioritized improved
access to accurate diagnosis and early treatment of
malaria with the aim to reduce disease burden and
lower the high case fatality rate. Challenges to this strat-
egy are many and include the absence of diagnosis or
delay in diagnosis, which may lead to an evolution of
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malaria diagnosis is mostly based on microscopy, which
requires a power source, a microscope, staining solution,
and a well trained technician. To maintain the capacity
to provide precise and reproducible thick smear results
to the population a large initial investment is required
followed by regular assessment and frequent training of
microscopists throughout this largely rural country.
With the scarce resources of community health centres
(CHC), reliable, accurate and accessible microscopy
capacity is rare at the community level. Health workers
and CHC budgets must also ensure that other malaria
control strategies such as insecticide-impregnated bed
nets are also available to their target population. More-
over, slide staining and reading times are relatively long
when compared to RDTs processing time. This delay in
diagnoses may also delay treatment initiation, thus wor-
sening the prognosis of infected children. The absence
of malaria diagnostics may also lead to an over-diagnos-
tic and treatment that jeopardizes the effectiveness of
available anti-malaria drugs.
During the last decade, rapid diagnostic tests (RDTs)
using chromatography and ELISA technology have been
developed and largely used in field studies [5-7]. These
diagnostic strips are based on antigens expressed by the
parasite during the erythrocyte stage such as histidine-
rich protein-2 (HRP2) [8-10] or lactate dehydrogenase
(LDH) [11]. HRP2 is involved in haemozoin formation,
while [12] Plasmodium falciparum LDH catalyzes the
conversion of lactate into pyruvate and nicotinamide
adenine dinucleotide (NADH) [13], a reaction essential
to parasite survival. LDH is produced only by living
parasites [14] as they need energy to ensure their devel-
opment in the course of the asexual life cycle. The
enzyme is short lived with a half-life of about 2 to 4
days. Some advantages of LDH-based RDT compared to
HRP2-based tests are detection of current infections and
discrimination of P. falciparum species from non-falci-
parum species that cause less severe disease.
The purpose of this study was to evaluate the utility of
parasite-based LDH (pLDH) RDT in Mali under field
conditions, to calculate the diagnostic values (positive
and negative predictive value and, sensitivity and specifi-
city) of the RDT compared to microscopy and to assess
the accuracy of the RDT as a diagnostic method in
malaria drug efficacy studies using the WHO 14 days In
vivo protocol. This study was conducted in 2003 when
choroquine was still the first line malaria treatment in
Mali.
Methods
Study areas and period
Four health centres participated to this multicentre
study; the community health centre of Faladie, a village
located 80 km north-west of Bamako; the health clinic
of Kolle, a village situated 60 km south-west of Bamako;
the paediatric intensive care unit of Gabriel Touré Hos-
pital in Bamako; Point G hospital (PGH) and the sec-
ondary health centre of District V in Bamako. The study
was conducted simultaneously in all health centres dur-
ing a period of intense malaria transmission from Sep-
tember 2003 to December 2003.
Study population and design
A total of 725 patients were enrolled in the study with a
sex ratio of 1.13:1 female to male. The study population
in Faladie consisted of children aged 0 to 9 years attend-
ing the health centre for malaria related symptoms and
asymptomatic pregnant women attending the clinic for
prenatal visits. In Kolle, all patients attending the clinic
were included in the study without any age restriction.
The study population in Gabriel Touré Hospital con-
sisted of children admitted to the paediatric ward with
fever. Patients from Point G hospital (PGH) were
referred to the Department of Epidemiology of Parasitic
Diseases Laboratory due to the proximity of the two
institutions. At the health centre of District V, the study
population included pregnant women attending the pre-
natal clinic and a scheduled vaccination programme.
After administering the informed consent, participants
were allocated an identification number and clinically
examined by the study doctors. In all these sites, partici-
pants received a finger prick in order to make a thick
smear and the RDT. In Faladie and Kolle, patients posi-
tive for malaria by thick smear or RDT were given chor-
oquine and asked to attend the clinic at days 1, 2 3, 7
and 14 for efficacy assessment. The study was approved
by the ethical committee of the Faculty of Medicine,
Pharmacy and Dentistry of Bamako, Mali.
Laboratory techniques
A thick smear was made for each patient and stained
with 3% Giemsa for 45 minutes. Parasite density was
obtained by counting the number of parasites per 300
leukocytes and using an estimate of 7500 leucocytes per
mm
3 of blood for quantification. OptiMal-IT was used
according to the procedure recommended by the
manufacturer.
Drug efficacy follow-up
In Kolle and Faladie, participants were followed for 14
days for drug efficacy assessment. After the initial test-
ing and drug administration, patients were asked to
return on days 3, 7 and 14. All the 3 doses of the choro-
quine were given at the health centre. Sulfadoxine-pyri-
methamine (SP) was used as second-line treatment in a
single dose of 1.25mg/kg when either the thick smear
and/or OptiMal-IT was positive during patient follow-
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WHO definitions [15]; early therapeutic failure (ETF),
late therapeutic failure (LTF) and satisfactory clinical
response (SCR). The three levels of parasitological
response as defined by WHO [15] were also used.
Quality control and OptiMal-IT acceptability
All thick smears were stained and read immediately at
the study site by trained microscopists. Smears were
then read by a second microscopist for quality control.
Additionally, 10% of thick smears were re-examined by
a third reader. OptiMal-IT tests were read indepen-
dently by two technicians. A third reader was used as a
tie breaker if the two readers disagree on their reading.
To assess the providers experience with the RDT, health
care providers were asked to complete a brief question-
naire which aimed to collect their feedback on the test
and its ease of use. The questionnaire was self-reported,
anonymous and conducted after the test completion.
Data analysis
Data were recorded on case report forms and laboratory
logs sheets. Data were analyzed using Access 2007 and
SPSS 13.0 software. We used a Chi-Squared or Fisher’s
exact test to compare frequencies of malaria detected
cases. Kappa statistics were used to assess test concor-
dance. The sensitivity, specificity and the predictive
values of both tests were also computed using micro-
scopy as the gold standard.
To assess the relationship between parasite density
and OptiMal-IT results, we defined 4 groups of parasite-
mia (25-1,000 parasites/mm
3; 1,025-2,500 parasites/
mm
3; 2,525-5,000 parasites/mm
3 and more than 5,000
parasites/mm
3). The correlation between OptiMal-IT
detection level and parasites count was assessed for each
of these groups.
Ethical considerations
Ethical approval was granted by the Faculty of Medicine,
Pharmacy and Dentistry IRB Committee of the Univer-
sity of Bamako, to carry out this research. Written
informed consent was obtained from all individuals par-
ticipating in interviews. Confidentiality was maintained
with use of study number during the data analysis
process.
Results
The distribution of participants by study site is shown in
Table 1. Gabriel Toure Hospital (GTH) and Point G
hospital (PGH) population were comprised of children
less than 10 years old, while in District V, the health
clinic centre offers services only to pregnant women.
Antimalarial drug efficacy follow-up was conducted only
in Faladie and Kolle (142 patients included out of 725
(19.6%). Study participants attendance and follow-up are
described in Figure 1.
Parasite detection and level of resistance
Overall, our results indicated that 56.5% of patients pre-
senting with fever or other malaria clinical symptoms
had a positive thick smear, whereas 58.2% were positive
by OptiMal-IT. Table 2 summarizes the comparison
between thick smear microscopy and OptiMal-IT test
results in all study sites.
Based on the WHO classification, 58% of patients have
parasites sensitive to choroquine and patients with early
treatment failure (ETF) were observed in 6% of cases.
Using the same clinical resistance definition, late treat-
ment failure (LTF) was reported in 12% of participants
while late parasitological failure (LPF) was reported in
24% of participants (table 3).
Among the 102 pregnant women who attend the Dis-
trict V health clinic, 12 malaria cases were diagnosed
using thick smear, while OptiMal-IT test revealed eleven
cases of malaria.
Diagnostic parameters
OptiMal-IT identified 13 malaria cases which were not
diagnosed by microscopy, whereas thick smear analyses
revealed 11 samples which were negative by OptiMal-
IT. Overall, using thick smear as the reference technique
the sensitivity of OptiMal-IT was 97.2% (95% CI, 0.96-
0.99), with a specificity of 95.4% (95% CI, 0.93-0.98).
Positive and negative predictive values were 96.7% (95%
CI, 0.95-0.98) and 96.1% (95% CI, 0.94-0.98) respec-
tively. Concordance () was 0.93 (table 4).
OptiMal-IT detection levels
OptiMal-IT was able to identify 97.2% of malaria cases
detected by thick smear at all parasite densities. All
malaria cases with parasitemia higher than 1000 para-
sites/μl were detected by OptiMal-IT test (table 5). In
addition to asexual stage, P. falciparum gametocytes
were also diagnosed by the rapid test. Importantly, spe-
cies other than P. falciparum were identified. Plasmo-
dium ovale (P. ovale) infections were only detected at
2525 parasites/μl and above. Plasmodium malariae (P.
Table 1 Distribution of study patients by study site and
sex.
Study site Female Male Total
Faladie 111 154 265
Gabriel Toure Hospital 53 73 126
Point G Hospital 68 84 152
Kolle 51 29 80
District 5 medical centre 102 0 102
Total 385 340 725
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Figure 1 Study profile of study patients visit at study site. OptiMal-IT, thick smear test and drug efficacy follow-up outcome.
Table 2 Distribution of thick smear and OptiMal-IT
malaria positive cases by study site
Study site Thick smear
n (%)
OptiMal-IT
n (%)
p value
Faladie 266 (78.6) 263 (77.6) 0.78
Gabriel Toure Hospital 104 (64.4) 104 (74) 0.13
Point G Hospital 151 (26.5) 137 (30.7) 0.43
Kolle 78 (84.6) 75 (81.3) 0.58
District 5 medical centre 97 (11.3) 100 (11.9) 0.90
Table 3 Levels of parasitological and clinical resistance
determined by thick smear
Level of resistance
ETF (%) LTF (%) LPF (%) ACPR (%)
Thick smear 9 (6) 17 (12) 34 (23) 82 (58)
ETF; Early treatment failure, LTF; Late treatment failure, LPF; Late
parasitological failure, ACPR; Adequate clinical and parasitological response.
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sites/μl and beyond with only 40% of infections below
this treshold detected.
Dynamics of pLDH after malaria treatment
There was no significant difference between diagnostic
techniques at day 0 (odd ratio: 0.99, 95% CI: 0.70-1.40),
day 3 (odd ratio: 1.05, 95% CI: 0.65-1.70) and day 14
(odd ratio: 1.10, 95% CI: 0.68-1.80) respectively (Figure
2). OptiMal-IT had a higher false positive test 7 days
after the treatment compared to thick smear (odd ratio:
3.70, 95% CI: 1.94-7.04) (Figure 2).
Acceptability of the test by health providers
Health providers had previous knowledge and some
experience with the OptiMal-IT test and found it easy
to use and store. In fact, more than 99% were able to
use the test after a training of one hour compared to at
least a week when laboratory technicians are trained to
discriminate malaria species using microscopy. OptiMal-
IT storage at room temperature was described to be an
advantage (table 6).
Discussion
Our Findings suggest that OptiMal-IT test is an effective
tool in the diagnosis of malaria. We also found that the
test was effective in the follow-up of malaria drug effi-
cacy with some limitations due to the discrepancy
observed at day 7. Finnaly, we found that health care
providers have a good understanding about the test and
field practicians sites preferred OptiMal-IT test com-
pared to thick smear.
We have found that OptiMal-IT was comparable to
thick smear microscopy which remains the current gold
standard for malaria diagnosis. In an earlier study of the
first generation OptiMal-IT test in western Uganda,
Jelinek et al [16] observed a test specificity of 62.2% and
a sensitivity of 58.8%, well below what was observed in
this study. This difference may be explained by the dif-
ference in the accuracy of the thick smear reading and
the improvements made in the design of the second
generation OptiMal-IT test [17]. Palmer et al [18] and
Dolo et al [19] observed results similar to our findings
in field studies conducted respectively in Honduras and
in Mali with analogous sensitivity, specificity and Kappa
concordance. Our thick smears were read by 2 indepen-
dent readers with one at the field site and a second
more experienced reader in the laboratory in Bamako.
On discordant cases, a third reader defined as a tie
breaker was asked to confirm or infirm the results. The
same reading method was used to determine OptiMal-
IT test positivity. This quality control may have
improved our data by removing false positive thick
smears and OptiMal-IT tests, thus improving our posi-
tive and negative predictive values. This high positive
predictive value is reflective of the high prevalence of
malaria during malaria transmission season.
OptiMal-IT test was found sensitive and specific for
malaria infection in a variety of populations in Mali.
S i m i l a ro b s e r v a t i o n sw e r em a d eb yM a l t h aet al [20]
when OptiMal-IT test was compared to other RDTs.
This would support the use of OptiMal-IT test to detect
malaria in health centres without access to microscopes.
Recent studies conducted by WHO [21] and research
teams in Africa [22,23] concur with our findings.
When we assessed the ability of OptiMal-IT to detect
malaria during pregnancy, we found that eleven out of
the 12 cases of malaria in this group of 102 pregnant
women detected by thick smear were diagnosed by
OptiMal-IT. This reveals the great advantage OptiMal-
IT test may have in women at risk of having adverse
fetal outcomes due to malaria in pregnancy. Findings by
Limanggeni et al [24] suggest that a positive maternal
OptiMal-IT test is a predictor of low birth weight in
Malawi newborns. These observations are supportive of
the used of OptiMal-IT test as an adequate screening
tool for the detection of clinically significant parasitemia
in the pregnant population.
Similarly to a study conducted by Cooke et al [25], we
found that OptiMal-IT test sensitivity increases with
parasitemia. All P. falciparum malaria cases with
Table 4 Diagnostic values of OptiMal-IT compared to thick smear as reference technique.
Thick smear
Positive Negative Sensitivity (%) Specificity (%) *PPV (%)
+NPV (%) Frequency of positive (%)
OptiMal-IT positive 379 13 97.2 95.4 96.7 96.1 58.2
OptiMal-IT negative 11 271
Frequency of positive (%) 56.5
*PPP; Positive predictive value; NPV;
+Negative predictive value
Table 5 Relationship between Plasmodium falciparum
parasites density and OptiMal-IT
Parasitemia per mm3 of blood
25-1000
n (%)
1025-2500
n (%)
2525-5000
n (%)
>5000
n (%)
OptiMal-IT positive 41 (89.1) 27 (100) 22 (100) 259 (100)
OptiMal-IT negative 5 (15.9) 0 (0) 0 (0) 0 (0)
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were detected as previously described [20]. However,
almost 16% of blood stage asexual forms with parasite-
mia less than 1000/μl were not detected. This observa-
tion highlights the fact that an improvement needs to be
done to reduce the detection limit of this RDT. Addi-
tional improvement may include the quality of packa-
ging and the accuracy of information in the kit [26]. If
these improvement are accomplished it may allowed the
use of this test as a screening tool as proposed by Ishen-
goma et al [27]. Moody et al [7] reported that one of
the pan-specific monoclonal antibodies has a lower
affinity in attaching to P. ovale antigens. This hypothesis
is supported by the genetic diversity of the encoding
gene which may prevent the binding of monoclonal
antibodies to their targets [28].
The rapid clearance of pLDH enzyme following suc-
cessful treatment was documented in participants who
enrolled in a 28 days drug efficacy study [29]. We
observed a significant difference between thick smer and
OptiMal-IT in the frequency of a positive test at day 7
after treatment. This difference can be explained by the
exclusive presence of Pf a l c i p a r u mgametocytes in
twelve participants samples which were not taken into
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Figure 2 Dynamics of OptiMal-IT test positivity during patient follow-up after a malaria treatment. The day of follow-up is on the × axis
and the proportion of positive cases on the y axis. Results from both tests were comparable during follow-up except for day 7 when the
proportion of cases detected by OptiMal-IT was statistically higher compared to the proportion observed with thick smear
Table 6 OptiMal-IT test approval by health care providers
Perception of test quality Number of respondents Frequency
Processing Easy 718 99.3
Acceptable 5 0.7
Difficult 0 0
Handling and storage Good 708 99.2
Acceptable 5 0.7
Poor 1 0.1
Prior knowledge about the test Yes 528 77.8
No 151 22.2
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cytes is the major drawback of OptiMal-IT in drug effi-
cacy monitoring [30]. Previous studies [29,31] have
found similar results prompting the question whether
this observation may limit the use of pLDH based tests
in the monitoring of drug efficacy. However, malaria is
known to be lethal in children if not detected and trea-
ted promptly. Most cases occur in areas where there is
limited access to health clinics and almost no access to
microscopes and power sources. With the introduction
of ACTs, pLDH-based RDTs may provide tools for
malaria detection as well as treatment efficacy in these
remote areas as recommended my Houze et al [29].
Results confirmation may be provided by regional refer-
ence centres which have tools to diagnose and quantify
parasites density. With the increased use of ACTs, we
expect less false-positive RDT results due to gameto-
cytes because artemisinins are gametocytocidal and
gametocytemia on day 7 is rare [32].
Finally, we found that clinicians in remote clinics as
well as in reference hospitals are familiar with RDTs.
Acceptance of RDT by health care providers and the
need to limit antimalarial drug administration to only
infected patients in a timely manner supports the imple-
mentation of pLDH-based RDTs in rural clinics and
health centres without microscopy.
Conclusion
Even though its limitations for malaria drugs efficacy
follow-up related to its inability to count parasite load
and the positivity of the test in presence of gametocytes,
OptiMal-IT has a good Kappa concordance. The test
may be suitable for therapeutic follow-up of patients in
areas without access to microscopes or a power source
to use conventional malaria diagnostic techniques. How-
ever, a confirmation of clinical resistance levels of these
remote areas using thick smears results should be
required. In addition, the ability of the test to detect
parasites at the gametocytes stage may be a great advan-
tage when patients will be screened during low trans-
mission season in order to identify gametocytes carriers.
These carriers may be treated with adequate drug to
reduce transmission during the raining season.
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